Focal Therapy for Prostate Cancer: Complications and Their Treatment
暂无分享,去创建一个
R. V. D. van den Bergh | G. Gandaglia | C. Fankhauser | I. Tsaur | G. Marra | F. Preisser | V. Kasivisvanathan | F. Zattoni | A. Kretschmer | C. Kesch | D. Tilki | M. Valerio | I. Heidegger | A. Rakauskas | F. Ceci
[1] H. G. van der Poel,et al. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. , 2021, European urology oncology.
[2] M. Emberton,et al. Detailing sexual outcomes after treatment of localised prostate cancer with focal therapy using various energy sources: protocol for a mixed-methods study , 2020, BMJ Open.
[3] S. Raman,et al. Predicting Pathologic Tumor Size in Prostate Cancer Based on Multiparametric Prostate MRI and Preoperative Findings. , 2020, The Journal of urology.
[4] X. Cathelineau,et al. Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence. , 2020, The Journal of urology.
[5] A. Sidana,et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. , 2020, European urology.
[6] J. von Hardenberg,et al. Prospective Feasibility Study of Single-Shot Antibiotic Prophylaxis in Transrectal Focal Ablation of Prostate Cancer , 2020, Urologia Internationalis.
[7] D. Eberli,et al. Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications. , 2020, Urologic oncology.
[8] P. Royce,et al. Survival and quality of life outcomes of high-intensity focused ultrasound treatment of localized prostate cancer , 2020, Prostate international.
[9] H. Ahmed,et al. A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer , 2020, Translational andrology and urology.
[10] Jiawei Shi,et al. Radical prostatectomy versus brachytherapy for clinically localized prostate cancer on oncological and functional outcomes: a meta-analysis , 2020, Translational andrology and urology.
[11] Run Wang,et al. Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management , 2019, Medical sciences.
[12] E. Barret,et al. Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardized Methodology. , 2019, Journal of endourology.
[13] H. Ahmed,et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. , 2019, European urology.
[14] Prashanth Rawla,et al. Epidemiology of Prostate Cancer , 2019, World journal of oncology.
[15] Raj Persad,et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer , 2018, European urology.
[16] F. Hamdy,et al. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. , 2018, Health technology assessment.
[17] M. Emberton. Has tailored, tissue‐selective tumour ablation in men with prostate cancer come of age? , 2018, BJU international.
[18] D. Margolis,et al. MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.
[19] H. Ahmed,et al. A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. , 2017, Urologic oncology.
[20] A. Ouzzane,et al. Focal therapy as primary treatment for localized prostate cancer: definition, needs and future. , 2017, Future oncology.
[21] Yipeng Hu,et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy , 2017, British Journal of Cancer.
[22] J. Coleman,et al. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project , 2017, Prostate Cancer and Prostatic Diseases.
[23] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[24] Antonio Alcaraz,et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Oncology.
[25] Shyam Natarajan,et al. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology , 2017, The Journal of urology.
[26] E. Barret,et al. Focal Therapy for Prostate Cancer: An "À la Carte" Approach. , 2016, European urology.
[27] H. Ahmed,et al. The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. , 2016, European urology.
[28] Henry Rusinek,et al. Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. , 2015, The Journal of urology.
[29] Ian A. Donaldson,et al. Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting , 2015, European urology.
[30] P. Han,et al. Management of Catheter-Related Bladder Discomfort in Patients Who Underwent Elective Surgery. , 2014, Journal of endourology.
[31] Brenda J. Crowe,et al. Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis , 2014, BMC Pulmonary Medicine.
[32] Nathan Lawrentschuk,et al. The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review , 2014, European urology.
[33] P. Pinto,et al. Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up , 2014, Current opinion in urology.
[34] J. Stanford,et al. Long-term functional outcomes after treatment for localized prostate cancer. , 2013, The New England journal of medicine.
[35] H. Ahmed,et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study , 2012, The Lancet. Oncology.
[36] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[37] F. Schmidt. Meta-Analysis , 2008 .
[38] T. H. van der Kwast. Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology. , 2018, European urology.
[39] H. Ahmed,et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. , 2015, European urology.
[40] H. Thomas. On clinical management. , 2005, The Health service journal.
[41] K. Shadan,et al. Available online: , 2012 .